top of page
Pharma R&D
Pharma R&D
Pharma R&D
Pharma R&D
Solving the Problem
What Do We Do
Developed clinically validated algorithms to determine the health of a patient’s immune system.
How Do We Do It?
Use proprietary algorithms, an extensive IP portfolio, advanced analytics, AI and machine learning capabilities.
Predict cancer progression
Identify genomic and clinical data
Apply proprietary genomic algorithms
Predict response to therapies and treatments
Profile diseases using AI/ML algorithms
Optimize drug development through Genomic Data Services
GMDx analytics (31 granted patents)
The GMDx Breakthrough
Innate Immune Fitness (IIF) Test
The GMDx Innate Immune Fitness (IIF) Score is the most accurate test developed today for predicting how patients will respond to cancer immunotherapy treatments.
IIF significantly outperforms standard tests like TMB and PD-L1.
GMDx IIF
TMB
PD-L1
IIF: Innate Immune Fitness, TMB: Tumor Mutation Burden,
PD-L1: Cell-based Biomarker, NPV: Negative predictive value
Immune System Health
Determination and Use Cases
bottom of page